Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Vertically integrated cannabis company Sunniva’s (CSE: SNN) (OTCQX: SNNVF) core subsidiaries and licensed tenant cultivators are gearing up to supply the multibillion dollar recreational and medical cannabis industries in California. To view the full article, visit: http://cnw.fm/ziE2C.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $6.1486, up 4.13%, on 132,328 volume with 300 trades. The average volume for the last 60 days is 34,668 and the stock's 52-week low/high is $5.7358/$16.00.

Recent News

• CannabisNewsBreaks – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Actively Targets Cannabis Market in California
• Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Floats on Rising Vaporizer Trends
• CannabisNewsBreaks – Canada Legalizes Recreational Marijuana

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has filed an important new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $2.01, up 5.24%, on 183,278 volume with 324 trades. The average volume for the last 60 days is 270,297 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

• Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders
• VIDEO: Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX)
• Farm Bill Legislation May Springboard Federal Hemp Acceptance

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) (“FinCanna”) a royalty company for the U.S. licensed medical cannabis industry is pleased to announce that following higher than anticipated demand the Company has increased the size of its previously announced non-brokered private placement financing.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.2242, up 5.21%, on 73,547 volume with 54 trades. The average volume for the last 60 days is 35,770 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

• FinCanna Increases Private Placement to $6.1 Million
• Coverage Initiated for FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) via NetworkNewsWire
• CannabisNewsBreaks – Canada Legalizes Recreational Marijuana

Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabinoids (CBD), nutraceutical and pharmaceutical fields, medical devices, as well as research and development, is expanding its full spectrum cannabinoid (CBD) chocolate line with three unique new products.

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.80, up 2.56%, on 28,011 volume with 37 trades. The average volume for the last 60 days is 12,975 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

• Earth Science Tech, Inc. Expands its Full Spectrum Cannabinoid (CBD) Chocolate Line with Three New Unique Products
• Earth Science Tech, Inc. Aligns with AATAC to Reach up to 90,000 Retail Outlets
• Earth Science Tech, Inc. (ETST) Subsidiary Readies International Marketing, Sales Launch of MSN-2 Home Medical Testing Kit for Women

First Cobalt Corp. (TSX-V: FCC) (OTCQX: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

The recent publication by First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) (ASX: FCC) of drill results from its Iron Creek Project in Idaho is good news for the North American cobalt community. It raises hope of lessened dependence on foreign supplies of the metal, now categorized as a critical mineral commodity by the United States Geological Survey (USGS).

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.3546, off by 1.55%, on 132,561 volume with 70 trades. The average volume for the last 60 days is 177,775 and the stock's 52-week low/high is $0.3302/$1.3041.

Recent News

• First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Announces New Mineralization in Idaho that May Boost US Production
• First Cobalt Announces Results from AGM
• First Cobalt Extends Mineralization at Iron Creek and Initiates Metallurgical Study

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

CannabisNewsAudio announces the Audio Press Release (APR) titled "Farm Bill Legislation May Springboard Federal Hemp Acceptance," featuring Marijuana Company of America Inc. (OTC Pink: MCOA). To hear the CannabisNewsAudio version, visit: http://cnw.fm/ER4Zp. To read the original editorial, visit: http://cnw.fm/WP4fi. Also today, CannabisNewsWire released a report on the company detailing how progressive trends in the adoption of hemp-derived products continue to boost the prospects of Marijuana Company of America and its hempSMART™ brand, which announced on June 19 the rollout of its latest cannabidiol-derived cosmetic product for people seeking an all-natural botanical moisturizer.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0384, up 0.52%, on 7,074,869 volume with 359 trades. The average volume for the last 60 days is 7,181,364 and the stock's 52-week low/high is $0.0195/$0.0728.

Recent News

• CannabisNewsAudio Announces Audio Press Release (APR) on Marijuana Company of America Inc. Spearheading Efforts, Staking Claims in Hemp Cultivation
• Marijuana Company of America, Inc. (MCOA) Launches CBD Infused Facial Moisturizer through hempSMART™ Subsidiary
• CannabisNewsWire Announces Rising Opportunity in Hemp Industry with Shifting Legislation Tides

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (TSX: TGOD).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) (the “Company” or “TGOD”) is pleased to announce that Prem Virmani has been appointed Chair of TGOD’s Beverage Science and Research Division. Also today, the company was highlighted in a news story on Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") and its completion of the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ:TSX") and the Horizons Emerging Marijuana Growers Index ETF ("HMJR:NEO").

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (TSX: TGOD), closed the day's trading session at $6.48, up 1.09%. The stock's 52-week low/high is $3.50/$8.28.

Recent News

• Prem Virmani Joins The Green Organic Dutchman as Chair of Beverage Science and Research Division
• Horizons ETFs Completes Rebalances of its Marijuana-focused ETFs
• Canadian Cannabis Producers Expanding Growing Capacities on the World Stage

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Global technology and value-added solutions group Net Element’s (NASDAQ: NETE) subsidiary, Unified Payments, provides a suite of solutions that keep service to the customer flowing “any time, any place, any payment”. To view the full article, visit: http://nnw.fm/Ew7AJ.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

• Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
• Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
• Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
• Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.35, up 4.11%, on 54,150 volume with 247 trades. The average volume for the last 60 days is 372,164 and the stock's 52-week low/high is $2.556/$33.51.

Recent News

• NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Takes Cutting-edge Approach to Intelligent Payment Solutions
• NetworkNewsWire Releases Exclusive Audio Interview with Net Element, Inc. (NASDAQ:NETE)
• NetworkNewsBreaks – Net Element, Inc.’s (NASDAQ: NETE) Proprietary Netevia Platform Highlighted in Research Note by JGR Capital

Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

CryptoCurrencyWire ("CCW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Virtual Crypto Technologies Inc. (OTCQB:VRCP). To view the full publication, titled “Cryptocurrency and Blockchain Innovators Poised to Reap Rewards as Fintech Reshapes How Money Is Used,” visit: http://nnw.fm/hIn7J.

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website, www.virtual-crypto.com, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

• Downloadable NetoBit Trader app link and contact forms for more information
• MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
• Improved security utilizing https certificates to protect personal information and site integrity
• Media room with downloadable product brochures, corporate presentations and other relevant content
• Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
• Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.149, up 6.43%, on 59,312 volume with 22 trades. The average volume for the last 60 days is 36,910 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News

• CryptoCurrencyWire Announces Publication on Red Hot Market Opportunities for Crypto and Blockchain Innovators
• Cryptocurrency and Blockchain Innovators Poised to Reap Rewards as Fintech Reshapes How Money Is Used
• Virtual Crypto Technologies Inc. (VRCP) Launches New Point-of-Sale Terminals to Boost Cryptocurrency Accessibility

Koios Beverage Corp. (CSE: KBEV) (OTC: SNOVF)

The QualityStocks Daily Newsletter would like to spotlight Koios Beverage Corp. (SNOVF).

Koios Beverage Corp. (CSE:KBEV) (OTC:SNOVF), an emerging functional beverage company with a wide distribution network, announces it has engaged the corporate communications expertise of NetworkNewsWire ("NNW").

Koios Beverage Corp. (CSE: KBEV) (OTC: SNOVF) develops and distributes nature-based products that boost brain function, enhance health, and improve productivity. Its core vision is to help a billion people worldwide live more productively through the development of nootropics, which are supplements that improve cognitive abilities.

The company’s flagship product, Koios, is a GMP-certified dietary supplement. Made from natural ingredients and backed by science, Koios is designed to improve focus, memory, mental drive, clarity and energy. The company produces Koios in the following formulations:

• Powder supplements containing nootropics as well as caffeine and lion’s mane and chaga mushrooms;
• Vegan-friendly capsules;
• Canned beverages containing nootropics along with MCT oil to burn fat and increase metabolism.

Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. The global field of nootropics is growing rapidly and expected to reach USD $6,059.4 Mn by 2024 with a CAGR of 17.9 percent from 2016 to 2024.

According to media reports, there is believed to be significant and growing use of nootropics among high-achieving students and professionals. The UK’s leading Guardian newspaper found that nootropics are commonly used in Silicon Valley by computer industry professionals who want to “hack” their minds and maximize their productivity without any possible negative effects on the brain.

Koios was born out of the personal struggles of its founder and CEO, Chris Miller, who has ADHD. Miller found that the symptoms of his condition held him back when navigating the competitive modern workplace. Unhappy with the effects of the Adderall he was prescribed, Chris began a search for a natural remedy that would improve his attention and mental capacity.

Speaking of his struggles at this time, Miller says, “Coffee and energy drinks were no longer helping me. Eventually, I was drinking so much caffeine that I was beginning to notice negative and troubling health effects.” He adds, “I believed there had to be a better way. Better technology that the earth was providing that I could implement and not only boost my daily performance but take care of my brain and body long-term.” After years of experiments and with the help of leading scientists, he developed Koios, named after the Greek Titan who represented rational intelligence.

Koios contains the following ingredients, among others:

• Vitamin B12: Crucial for the function of the nervous system and the synthesis of DNA, B12 also helps in the creation of red blood cells.
• Vitamin B6: This vitamin is crucial for brain development among children and brain function in adults. B6 is also important in the production of key hormones: serotonin, which regulates mood, norepinephrine, which helps us handle stress, and dopamine.
• Huperzine A: Developed from the Chinese club moss plant, huperzine A is used on Alzheimer’s patients to boost their memories. It is also used to raise energy levels and alertness and is the subject of medical trials to test its efficacy when combined with other drugs.
• Bacopa: Also known as brahmi, bacopa is an Indian herb used in Ayurvedic medicine to improve concentration and memory. Modern science has recognized its effectiveness, and it is used to treat symptoms caused by Alzheimer’s disease, ADHD and anxiety.
• Ciwujia: Sports scientists have been interested in this herb since they heard of how mountain climbers in Tibet use it to boost their performance at high altitudes. Peer-reviewed research has shown that Ciwujia has clear positive effects on endurance.

A full breakdown of Koios’ active ingredients is available on the company website.

Additionally, safety is paramount for Koios, with all its products developed in a high-grade nutraceutical laboratory which is GMP-certified and in compliance with FDA guidelines. Koios only uses high-quality ingredients sourced from the best possible locations in order to deliver a product that is not only safe but also “one of the world’s greatest nootropic blends.”

The company’s products can be found online and in stores, both across the United States and internationally, via a continuously growing distribution network.

Koios CEO Chris Miller is supported by a team with strong credentials in medical supplement start-ups, corporate finance and sales, which includes CFO/Director Anthony Jackson, Director Scott Walters, Director Konstantine Lichtenwald and Vice President of Sales Gina Burrus.

With people seeking a mental edge and cognitive boost, Koios believes that there is an opening in the market for its nature-based, over-the-counter nootropics, especially when current prescription medicines have worrying side effects..

Koios Beverage Corp. (SNOVF), closed the day's trading session at $0.193, off by 6.99%, on 107,416 volume with 55 trades. The average volume for the last 60 days is 54,734 and the stock's 52-week low/high is $0.001/$0.5121.

Recent News

• Coverage Initiated for Koios Beverage Corp. (CSE: KBEV) (OTC: SNOVF) via NetworkNewsWire
• Cannavated Licenses Functional Beverage Formula to Keef Brands to Produce a Line of Cannabis-Infused Beverages
• CannabisNewsBreaks – Why Koios Beverage Corp. (CSE: KBEV) is “One to Watch”

BLOCKStrain Technology Corp. (TSX-V: DNAX)

The QualityStocks Daily Newsletter would like to spotlight BLOCKStrain Technology Corp. (DNAX).

BLOCKStrain Technology Corp. (TSX-V: DNAX.V) has developed the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry. To view the full interview with CEO, Robert Galarza, visit: https://youtu.be/bJixypv7NqI.

BLOCKStrain Technology Corp. (TSX-V: DNAX), a full-service software company headquartered in Vancouver, BC, Canada, has developed the first integrated blockchain platform that registers and tracks cannabis intellectual property (“IP”) from genome to sale. It is proprietary, immutable and cryptographically secure, thereby establishing a single source of truth for cannabis strains and their ownership.

With Canada set to legalize marijuana use for recreational purposes, and other jurisdictions following suit around the world, new challenges will emerge regarding the ability to provide a safe and legal inventory of a product that up until now was largely only available on the black market. Cannabis will be heavily tested and regulated by numerous regulatory bodies in Canada. The cannabis industry faces unique challenges that BLOCKStrain specifically helps it address, including:

• Mandatory Testing: Through BLOCKStrain’s platform and lab-testing partners, the process is more efficient and streamlined, cutting the administrative burden in half and getting products to market faster;
• DNA Based Product Validation: The underlying blockchain technology creates a genetic fingerprint that identifies and validates the product electronically so any participant on the platform, including consumers, can view and track what’s happening with that product from genome to sale;
• Intellectual Property: Third, and perhaps most importantly, the BLOCKStrain platform protects the intellectual property of growers and breeders. This is important for the industry’s growth as products evolve and develop. If a craft grower, for example, creates a popular strain with unique characteristics, it will be able to protect its intellectual property by simply registering the strain’s genome with BLOCKStrain and locking that data into the blockchain. It will reside there forever and will be readily accessible in the event of future disputes, bringing a level of trust to the industry and ensuring licensing fees are paid to all players in the market.

VERIFICATION = CERTIFICATION

BLOCKStrain’s genetics verification process is authentic and incredibly effective. User groups register by creating an account with BLOCKStrain, which starts the process. Organizations and independent growers submit seeds, flower and post-extraction product for testing to a registered and approved testing facility, which then submits test results to BLOCKStrain. Pre-existing data of genetic cannabis strains can also be submitted via BLOCKStrain verification administrators, with those results being added to the user group’s blockchain account. Submissions are entered into BLOCKStrain, and the transaction is completed and recorded.

Each time an item is tested and verified by the network, a Registration Affidavit is auto-generated and given a unique “BLOCKStrain Address” along with a traceable QR Code. Producers, patients and consumers are able to not only verify the test but can also rate the product, write reviews and share opinions. This detail is stored within BLOCKStrain and, just like the test results, cannot be tampered with or modified. Verification and certification are earned by all parties for their participation.

SAFE CONSUMER SUPPLY

BLOCKStrain demystifies the seed-to-sale process for all relevant stakeholders including producers, distributors, shippers, government agencies and consumers by creating a repository of cannabis genomes on an immutable, shared ledger. Thousands of cannabis strains exist and cultivators are breeding new strains all the time. The proliferation of cannabis strains can prove problematic for consumers since there are more than 500 known chemical compounds in a single plant. Furthermore, since several dozens of these compounds have been identified as pharmacologically active, it becomes more and more difficult for consumers to know what they are purchasing.

It is for this reason that being able to quantify the genetics, potency and equivalencies among cannabis products is crucial to the future of legalized cannabis. The difference is not so much in the name or brand attached to the cannabis, but the DNA of the plant itself. BLOCKStrain ensures product integrity, safety, regulatory compliance, product licensing and authenticity – all vital elements for the emerging cannabis industry.  This technology also bolsters the process of meeting government regulatory standards by providing real-time visibility of industry operations to agencies assigned to enforce and regulate cannabis activity.

INTELLECTUAL PROPERTY RIGHTS

BLOCKStrain allows for the defense of intellectual property rights for the grower with an authentic, verifiable chain of evidence embedded in the blockchain itself. Proof of ownership for a specific strain of cannabis is paramount in a multibillion dollar industry. Real life ownership disputes have already begun in the industry with legal battles underway. Unfortunately, the framework for resolving these disputes has yet to be defined and they are not likely to be resolved anytime soon.

Consumers and regulators alike want to know whether a cannabis product grown and sold at a local dispensary is safe and meets quality control standards. BLOCKStrain enhances trust of origin from genome-to-sale as cannabis flows through the supply chain, verifying critical steps in the process such as who is growing the plant, which seed is planted and where did it come from, whether pesticides were used, how much was grown, which tests are used to establish quality and potency, where the product is transported and how, and whether possession limits are meeting regulatory standards.

In summary, BLOCKStrain has developed the most comprehensive, secure and community-driven cannabis genetics archival platform for cannabis breeders and growers, large and small, to protect and release their varieties into the public domain, all while compensating and rewarding them for their contributions.

BLOCKStrain Technology Corp. (DNAX), closed the day's trading session at $0.28, off by 8.20%, on 326,360 volume. The stock's 52-week low/high is $0.105/$1.20.

Recent News

• View from the C-Suite: Robert Galarza, CEO, BLOCKStrain Technology Corp., tells his company's story. Filmed on June 21, 2018
• CannabisNewsBreaks – BLOCKStrain Technology Corp. (TSX.V: DNAX) Advances Company Know-how with New Advisory Board Member
• BLOCKStrain Technology Corp. (TSX.V: DNAX) Positioned to Benefit from Greater Consumer Spending

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the closing of its oversubscribed non-brokered private placement financing previously announced April 9, 2018 (the "Financing").

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0416, off by 26.28%, on 30,250 volume with 6 trades. The average volume for the last 60 days is 20,178 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

• PreveCeutical Announces the Closing of Oversubscribed Non-Brokered Private Placement
• CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Innovative Therapies as Alternative Medicine Market Surges
• NetworkNewsWire Releases Exclusive Audio Interview with PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H)